Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 5/20 | 0.52 |
| ▸ | HPGDS | O60760 | 4/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | FCER2 | P06734 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070379 | 1.00 | CAPN1 (0.52) | CAPN1HPGDSCTSBFPR3FPR2 | |
| SCHEMBL7765729 | 1.00 | CAPN1 (0.52) | CAPN1HPGDSCTSBFPR3FPR2 | |
| SCHEMBL7765736 | 1.00 | CAPN1 (0.52) | CAPN1HPGDSCTSBFPR3FPR2 | |
| SCHEMBL6070174 | 0.89 | ACE (0.45) | CAPN1 | |
| SCHEMBL7761900 | 0.84 | CAPN1 (0.59) | CAPN1CTSBFCER2MMP1 | |
| SCHEMBL7209524 | 0.84 | CAPN1 (0.59) | CAPN1FCER2MMP1 | |
| SCHEMBL7209529 | 0.84 | CAPN1 (0.59) | CAPN1FCER2MMP1 | |
| SCHEMBL7759040 | 0.83 | CPB2 (0.46) | — | |
| SCHEMBL7762727 | 0.83 | FCER2 (0.56) | CAPN1FCER2MMP1 | |
| SCHEMBL8344939 | 0.83 | FCER2 (0.56) | CAPN1FCER2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056947-B2 | For inhibiting (cysteine) proteases/caspases; for treatment of viral infections, stroke, neurodegenerative disease, and inflammatory diseases | GEORGIA TECH RESEARCH CORP. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040048327-A1 | Aza-peptide epoxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-11 | — | — | US | disclosed |
| US-5883121-A | INHIBITING ACTIVITY AGAINST CATHEPSIN, AND IS USEFUL FOR PREVENTION AND TREATMENT OF OSTEOPATHY SUCH AS OSTEOPOROSIS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1999-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048327-A1 | Aza-peptide epoxides | ANPEP, ENPEP, TMPRSS15 | CAPN1 431/4885HPGDS 123/4885CTSB 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.